Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$3.75
-$0.36(-8.76%)
At close: 4:00 PM EDT
$3.75
-$0.36(-8.76%)
Day’s Range― - ―
52-Week Range$1.62 - $5.06
Previous CloseN/A
Volume791.73K
Average Volume (3M)475.66K
Market Cap
$132.12M
Enterprise Value$63.07
Total Cash (Recent Filing)$6.71M
Total Debt (Recent Filing)$934.00K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding41,943,280
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.67Price Target Upside957.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$13.89M
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale & Regulatory ProgressA preliminary FDA bioequivalence determination plus validated blow-fill-seal production capable of ~1M units/week creates durable manufacturing advantage. High throughput and VAI reclassification reduce supply constraints, lower per-unit cost potential, and support rapid national launch and longer-term market share retention.
NRX-100 NDA Backed By Real-world EvidenceA submission model that pairs clinical trials with extensive RWE provides a structural regulatory and market access benefit. Broad RWE can strengthen label claims, support payer discussions, and shorten adoption cycles if FDA accepts the analytics approach, improving long-term commercial prospects beyond trial-only programs.
Improved Liquidity And Debt ReductionBecoming debt-free while completing multiple capital raises materially eases near-term financing pressure. Increased runway and reduced interest obligations improve capacity to execute regulatory filings, scale manufacturing and clinic rollout, and reduce forced-fire financing risk during key approval and launch windows.
Bears Say
Heavy Cash Burn & Negative EquitySustained large operating losses and negative equity signal an accumulated deficit and structural funding need. Ongoing negative free cash flow limits reinvestment capacity, increases dilution risk from future financings, and constrains flexibility to scale commercialization without persistent external capital.
Ongoing Dependence On External CapitalReliance on at-the-market equity programs and contingent clinic revenue is a structural vulnerability. Access to public equity can narrow or cost more if market conditions change, potentially delaying programs or forcing dilutive raises that affect long-term ownership, R&D pacing, and commercialization execution.
Commercial Channel & Market Execution RiskNeeding to establish two distinct go-to-market channels and displace entrenched compounding pharmacies imposes lasting execution costs. Payer, distributor and clinic adoption cycles are structural hurdles that can slow revenue scale, raise customer acquisition costs, and require sustained commercial investment.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $5.05 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $132.12M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.209 by -$0.249.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 41,943,280 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.209. Following the earnings report the stock price went down -5.03%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.67 (957.78% Upside)
$39.67 (957.78% Upside)
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system disorders and life-threatening conditions. Its publicly described pipeline has included drug candidates targeting severe depression/suicidality and other neuropsychiatric indications, and it has also disclosed work related to treatments for acute respiratory distress syndrome (ARDS) and related critical-care settings. The company’s operations center on drug development activities (research, clinical trials, regulatory submissions) and, where applicable, establishing commercialization pathways through partners or affiliated entities.
NRXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$39.67
▲(957.78% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
9.00%
Insiders
3.22% Mutual Funds
8.68% Other Institutional Investors
73.33% Public Companies and Individual Investors